- Home
- DNTH vs INVA Comparison
DNTH vs INVA Comparison
Compare DNTH & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- INVA
- Stock Information
- Founded
- DNTH 2015
- INVA 1996
- Country
- DNTH United States
- INVA United States
- Employees
- DNTH N/A
- INVA N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- INVA Health Care
- Exchange
- DNTH Nasdaq
- INVA Nasdaq
- Market Cap
- DNTH 1.4B
- INVA 1.1B
- IPO Year
- DNTH N/A
- INVA 2004
- Fundamental
- Price
- DNTH $33.67
- INVA $18.09
- Analyst Decision
- DNTH Strong Buy
- INVA Buy
- Analyst Count
- DNTH 11
- INVA 5
- Target Price
- DNTH $65.22
- INVA $35.60
- AVG Volume (30 Days)
- DNTH 516.1K
- INVA 716.4K
- Earning Date
- DNTH 11-07-2025
- INVA 11-06-2025
- Dividend Yield
- DNTH N/A
- INVA N/A
- EPS Growth
- DNTH N/A
- INVA N/A
- EPS
- DNTH N/A
- INVA 0.53
- Revenue
- DNTH $4,854,000.00
- INVA $370,229,000.00
- Revenue This Year
- DNTH N/A
- INVA $7.98
- Revenue Next Year
- DNTH N/A
- INVA $11.60
- P/E Ratio
- DNTH N/A
- INVA $34.05
- Revenue Growth
- DNTH 17.87
- INVA 12.02
- 52 Week Low
- DNTH $13.37
- INVA $16.52
- 52 Week High
- DNTH $40.16
- INVA $22.00
- Technical
- Relative Strength Index (RSI)
- DNTH 46.99
- INVA 51.74
- Support Level
- DNTH $32.28
- INVA $17.45
- Resistance Level
- DNTH $35.40
- INVA $18.31
- Average True Range (ATR)
- DNTH 1.59
- INVA 0.50
- MACD
- DNTH -0.20
- INVA 0.14
- Stochastic Oscillator
- DNTH 26.53
- INVA 57.53
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.